Role of Perirectal Fat in the Carcinogenesis and Development of Early-Onset Rectal Cancer

An Fu Pan,1,2 Nan Xin Zheng,1,2 Jin Wang,3 Jean Luc Tshibangu Kabemba,1,4 Kuo Zheng,1,2 Fu Shen,3 Wei Zhang,1,2 and Xian Hua Gao1,2

1Department of Colorectal Surgery, The First Affiliated Hospital, Naval Medical University, Shanghai, China
2Hereditary Colorectal Cancer Center and Genetic Block Center of Familial Cancer, Changhai Hospital, Shanghai, China
3Department of Radiology, The First Affiliated Hospital, Naval Medical University, Shanghai, China
4Department of General Surgery, Central Military Hospital, Kinshasa, Democratic Republic of the Congo

Correspondence should be addressed to Fu Shen; ssf_53@163.com, Wei Zhang; weizhang2000cn@163.com, and Xian Hua Gao; gxh505@126.com

Received 30 January 2022; Revised 24 February 2022; Accepted 5 March 2022; Published 22 March 2022

Academic Editor: Alessandro Granito

Copyright © 2022 An Fu Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. The incidence of early-onset rectal cancer (EOCRC) has been increasing since the past decade, while its underlying cause remained unknown. This study was aimed at clarifying the relationship between perirectal fat area (PFA) and EORC.

Patients and Methods. All patients with rectal cancer who received radical excision between January 2016 and December 2017 at our hospital were included. The fat series images of pelvic magnetic resonance imaging scans were obtained and PFA at the ischial spine level was calculated using the ImageJ software.

Results. A total of 303 patients were finally included and divided into two groups according to the median PFA: Group 1 (<20.2 cm², n = 151) and Group 2 (≥20.2 cm², n = 152). PFA positively correlated with body weight and body mass index. PFA increased with invasion depth, lymph node metastasis, TNM stage, tumor deposits, and vascular invasion. Patients with EORC had higher PFA than those with late-onset rectal cancer (LORC; P = 0.009). Among patients with stage I–III rectal cancers, those in Group 2 had significantly shorter disease-free survival (P = 0.010) and overall survival (P = 0.034) than those in Group 1, and PFA was an independent predictor of disease-free survival (OR: 1.683 [1.126–3.015], P = 0.035) and overall survival (OR: 1.678 [1.022–2.639], P = 0.046).

Conclusions. Patients with EORC had significantly higher PFA than those with LORC. PFA is positively correlated with T stage, N stage, TNM stage, tumor deposit, and vascular invasion and is an independent predictor of disease-free survival and overall survival. Therefore, perirectal fat may be involved in the carcinogenesis and development of EORC.

1. Introduction

Colorectal cancer (CRC) is a common malignancy worldwide [1]. Early-onset colorectal cancer (EOCRC) is usually defined as CRC occurring in patients aged <50 years. Since the 1990s, due to the widespread CRC screening in the general population older than 50 years, the incidence and mortality of late-onset colorectal cancer (LOCRC; CRC diagnosed in patients older than 50 years) have significantly decreased [2]. In contrast, the prevalence of EOCRC has rapidly increased in the past decades globally [3–6]. In the USA, it had been reported to rise from 8.6 per 100,000 in 1992 to 13.1 per 100,000 in 2016 [2]. In China, the age-standardized incidence rate of EOCRC increased by 2.76% per year from 1990 to 2016 [1]. Currently, EOCRC is ranked second in cancer prevalence and third in cancer mortality in American people younger than 50 years [7]. It accounts for 10–12% of all newly diagnosed CRC [2]. EOCRC is predicted to increase by >140% by 2030 [3, 8], and EOCRC will account for about 11% of colon carcinomas and 23% of rectal carcinomas [2]. A large study with 1,185,763 cases of CRC showed that EOCRC was more likely to be rectal cancer (vs. colon tumors) than LOCRC (40.0% vs. 28.5%, P < 0.0001) [9]. Therefore, it is necessary to explore the underlying cause of the increasing trend in early-onset rectal cancer (EOCRC).
Possible risk factors of EOCRC included global westernization of diets, increased consumption of red meats, stress, antibiotics, synthetic food dyes, sedentary behavior, and gut microbiota [6]. However, the underlying reason for the increasing trend of EOCRC remains unknown [2]. Some scientists had suggested that obesity would contribute to the increasing trend of EOCRC [10–13]. Overweight and weight gain had been reported to be associated with a higher incidence of EOCRC [14, 15]. Accumulation of abdominal fat has a similar effect on the risk of CRC [16]. Traditionally, body mass index (BMI) is the most used parameter for describing overall obesity because it can be easily calculated [17]. Parameters related to abdominal obesity, such as waist circumference, areas of abdominal adipose tissue, and visceral adipose tissue (VAT), have been proven to be more accurate in predicting many cancers types than the overall obesity-related parameters [18]. VAT can be precisely calculated using magnetic resonance imaging/computed tomography (MRI/CT) and can predict CRC incidence, development, and outcomes better than BMI [18–22]. Perirectal fat, a part of the visceral fat surrounding the rectum within the mesorectal fascia (MRF), is speculated to play a part in the progression of rectal cancer by secreting multiple cytokines and adipokines and having direct contact with the rectum. MRI has been widely used in the preoperative evaluation of rectal cancer [23]. MRI outweighs CT in measuring perirectal fat, as adipose tissues have a specific signal on MRI compared to the neighboring tissue [24]. The fat series of pelvic MRI was chosen to measure the perirectal fat area (PFA) because of the aforementioned reasons.

To the best of our knowledge, no studies have explored the role of PFA in the carcinogenesis and development of EOCRC. Hence, this study was aimed at investigating the impact of PFA on the age at diagnosis of rectal cancer and various tumor development-related parameters, including pathological TNM stage, tumor deposit, vascular invasion, and perineural invasion. In addition, the associations among PFA, body weight, BMI, and oncologic outcomes were also investigated.

2. Materials and Methods

2.1. Patients. All patients with rectal cancer undergoing radical resection at Changhai Hospital from January 2016 to December 2017 were carefully screened for inclusion in this research. The Colorectal Surgery Department of Changhai Hospital is a tertiary referral center that focuses on CRC treatment. Data of demographic variables, clinicopathological parameters, and oncological outcomes had been prospectively collected and updated in our CRC database. All inpatient, outpatient, operation, postoperative pathological reports, and electronic magnetic resonance (MR) images had been carefully reviewed. This study was approved by the ethics committee of the First Affiliated Hospital, Naval Medical University.

2.2. Inclusion Criteria and Exclusion Criteria. Patients were included if they met all of these criteria: (1) aged between 18 and 75 years; (2) rectal cancer within 15 cm from the anal margin under flexible colonoscopy; (3) pathologically confirmed rectal adenocarcinoma; (4) follow-up at our hospital for at least 1 year after the operation date; (5) had pelvic MR images in the picture archiving and communication (PACS) system of our hospital before the operation date; (6) underwent radical excision of rectal cancer in our hospital; and (7) complete clinicopathological data available in our database.

Exclusion criteria included the following: (1) patients with Lynch syndrome or familial adenomatous polyposis; (2) patients with synchronous or metachronous multiple primary CRC; (3) patients with cancers other than adenocarcinoma; (4) patients who only had local excision or biopsy of the rectal cancer; (5) patients who received preoperative treatment, including radiation, chemotherapy, target therapy, and immune therapy; (6) patients who did not have preoperative pelvic or rectal MR images in our PACS; (7) preoperative pelvic MR images were too obscure to measure PFA; and (8) preoperative pelvic MR images did not include fat series (DIXON-Fat, LAVA-Flex-Fat, or T1-Fat).

2.3. Follow-Up. Postoperative follow-up included digital rectal examination, chest X-ray or CT scan, liver ultrasound or contrast-enhanced MRI, pelvic-enhanced MRI, serum carcinoembryonic antigen, and carbohydrate antigen 19-9 levels. These examinations were carried out every 3 months for the first 2 years postoperatively, every 6 months for the following 3 years, and annually thereafter. Complete colonoscopy was performed 1 year after the surgery and every 1–3 years thereafter.

2.4. Measurement of PFA. The fat series (DIXON-Fat, LAVA-Flex-Fat, or T1-Fat) images of pelvic contrast MRI scans were obtained from the PACS. PFA was calculated at the ischial spine level. The fat area was measured using the ImageJ software (Figure 1(a)). First, a transverse pelvic MR image was obtained at the ischial spine level. The fat area was measured using the ImageJ software (Figure 1(a)). First, a transverse pelvic MR image was obtained at the ischial spine level (Figure 1(b)). The scale was set based on the attached ruler in the image (Figure 1(c)). Subsequently, the region of interest (PFA) was circled by hand (Figure 1(d)). Only mesorectal fat within the MRF (inside the pelvic wall muscle) was included. The outer unrelated region was removed (Figure 1(e)). The picture was transformed to an 8-bit image, and the automatic threshold was selected [24] (Figure 1(f)). The red region indicates the PFA (Figure 1(g)). Finally, the menu tool “analyze particles” was used to measure the area of the red region [25].

All measurements were performed independently by two physicians (AFP and NXZ), who were blinded to the clinicopathological parameters. Every result was compared between them. If the difference between two results was within 5%, the mean value was chosen as the final result; otherwise, discrepancies were resolved by discussion between the physicians, and with a senior radiologist after their discussion.

2.5. Statistical Analysis. All analyses were performed with the SPSS 22.0. The independent sample t-test, Mann–Whitney U test, and one-way analysis of variance were used in the comparative analysis of quantitative parameters. The Chi-square test and Fisher’s exact test were used in the comparative analysis of qualitative parameters. The relationships between PFA, body weight, and BMI were analyzed using Pearson’s correlation coefficient. The role of PFA on OS and DFS was analyzed using the Kaplan–Meier survival
analysis. Multivariate Cox analyses were selected to identify predictive parameters for OS and DFS. All parameters with statistical and clinical significance in the univariate analysis were included in the following multivariate Cox analysis. Multivariate analyses were performed with the forward stepwise method (likelihood ratio); the inclusion criterion was “$P < 0.05$,” and the exclusion criterion was “$P > 0.10$.” $P$ value $< 0.05$ was considered statistically significant.

3. Results

Of the 1,418 patients with rectal cancer who underwent surgery between January 2016 and December 2017 at our hospital, 303 (21.4%) were finally included in the study after excluding patients who had preoperative chemoradiotherapy ($n = 420$) or local excision ($n = 23$), other tumor types ($n = 12$), no pelvic MR image ($n = 241$), obscure MR images ($n = 11$), or no fat series image ($n = 408$). A flowchart of patient screening is shown in Figure S1.

3.1. Clinicopathological Features. The median and interquartile range of age at diagnosis and follow-up period were 62 (53–67) years and 48 (42–54) months, respectively. At diagnosis, the mean and standard deviation of body weight, BMI, and PFA were $64.4 \pm 10.1$ kg, $23.3 \pm 2.9$ kg/m$^2$, and $20.4 \pm 6.9$ cm$^2$, respectively. The 303 patients were classified into two groups using the median of PFA (20.2 cm$^2$): Group 1 (<20.2 cm$^2$) and Group 2 (≥20.2 cm$^2$).
Table 1: Comparison of quantitative variables between patients with lower and higher PFA.

| Clinicopathological variables | Perirectal fat area (cm²) | Group 1 (<20.2, n = 151) | Group 2 (≥20.2, n = 152) | P  |
|-------------------------------|--------------------------|--------------------------|--------------------------|----|
| Age (year)                    |                          | 61.66 ± 10.36            | 58.91 ± 10.34            | 0.022 |
| Height (cm)                   |                          | 164.25 ± 6.86            | 167.36 ± 7.03            | <0.001 |
| Body weight (kg)              |                          | 61.21 ± 9.64             | 67.59 ± 9.49             | <0.001 |
| Body mass index (kg/m²)       |                          | 22.63 ± 3.03             | 24.05 ± 2.48             | <0.001 |
| Carcinoembryonic antigen (ng/mL) |                        | 3.53 (2.09–7.19)         | 3.25 (1.53–7.73)         | 0.439 |
| Carbohydrate antigen 19-9 (U/mL) |                      | 6.97 (3.2–13.99)         | 6.41 (3.08–16.36)        | 0.805 |
| Length of hospital stay (d)   |                          | 11.93 ± 5.42             | 11.38 ± 4.95             | 0.361 |
| Length of postoperative hospital stay (d) |        | 8.33 ± 4.8               | 7.67 ± 4.62              | 0.223 |
| Tumor diameter (cm)           |                          | 3.75 ± 1.45              | 3.9 ± 1.75               | 0.400 |
| Positive lymph node           |                          | 1.46 ± 2.95              | 1.68 ± 2.78              | 0.503 |
| Total lymph node              |                          | 14.07 ± 4.03             | 15.11 ± 3.86             | 0.023 |

3.2. Comparison of Quantitative Variables between Patients with Lower and Higher PFA. Comparisons of quantitative variables between patients with lower PFA (Group 1) and higher PFA (Group 2) are shown in Table 1. Compared to Group 1, Group 2 had significantly younger age and higher height, body weight, BMI at diagnosis, and more retrieved lymph nodes (Table 1).

3.3. Comparison of Qualitative Variables between Patients with Lower and Higher PFA. Comparisons of qualitative variables between patients with lower PFA (Group 1) and higher PFA (Group 2) are shown in Table 2. Compared to Group 1, Group 2 had significantly more male patients, lymph node metastasis, tumor deposits, and higher TNM stage (Table 2, all P < 0.05).

3.4. Relationship between Body Weight, BMI, and PFA. Pearson’s correlation analysis showed that PFA was positively correlated with body weight (r = 0.375, P < 0.001) and BMI (r = 0.302, P < 0.001) (Figure 2).

3.5. Relationship between PFA, TNM Stage, Tumor Deposit, Vascular Invasion, Perineural Invasion, and Age at Diagnosis of Rectal Cancer. One-way analysis of variance showed that PFA increased with T stage; patients with T3 stage had significantly higher PFA than patients with T1 stage (Figure 3(a), P < 0.05). Similarly, PFA increased with the N stage (Figure 3(b), P = 0.027); patients with N1 and N2 stage had significantly higher PFA than patients with N0 stage (Figure 3(b), both P < 0.05). Patients with distant metastasis had slightly lower PFAs than those without distant metastasis; however, there was no statistical significance (Figure 3(c), P = 0.663). For the TNM stage, PFA increased from stage I to III but then decreased from stage III to IV (Figure 3(d), P = 0.022). Patients with stage III tumor had higher PFA than those with stage I and II (Figure 3(d), both P < 0.05). Patients with tumor deposits had higher PFAs than those without (Figure 3(e), P = 0.001). Patients with vascular invasion had higher PFAs than those without (Figure 3(f), P = 0.038). Patients with perineural invasion had similar PFAs than those without (Figure 3(g), P = 0.194). Patients with EORC had higher PFAs than those with LORC (Figure 3(h), P = 0.009).

3.6. Comparison of DFS and OS between Patients with Lower and Higher PFA. A total of 303 patients were classified into two groups based on the median of PFA: Group 1 (<20.2 cm², n = 151) and Group 2 (≥20.2 cm², n = 152). When all patients were analyzed, Group 2 had significantly shorter DFS (Figure 4(a), P = 0.041) and similar OS (Figure 4(b), P = 0.112) compared to Group 1. Patients with distant metastasis usually become thinner due to massive nutritional consumption by the tumor, which may lead to a decrease in PFA and interfere with the correlation analysis between PFA and survival duration. After excluding patients with distant metastasis (stage IV), Group 2 had significantly shorter DFS (Figure 4(c), P = 0.010) and OS (Figure 4(d), P = 0.034) than Group 1.

3.7. Univariate and Multivariate Cox Analyses of Potential Predictors of DFS in Patients with Stage I–III Rectal Cancer. The results of the univariate analysis showed that PFA, diabetes, tumor deposit, vascular invasion, invasion depth, and TNM stage were potential predictors of DFS (Table S1). Multivariate analysis showed that PFA [OR: 1.683 (1.126–2.0.003)], vascular invasion, and TNM stage were independent predictors of DFS (Table 3).

3.8. Univariate and Multivariate Cox Analyses of Potential Predictors of OS in Patients with Stage I–III Rectal Cancer. The results of the univariate analysis showed that PFA, tumor deposit, vascular invasion, invasion depth, and TNM stage were potential predictors of OS (Table S2). Multivariate analysis showed that PFA [OR: 1.678 (1.022–2.0.003)], vascular invasion, and TNM stage were independent predictors of OS (Table 4).

4. Discussion

Our study demonstrated that patients with PFA ≥ 20.2 cm² had significantly younger age at diagnosis; higher body...
### Table 2: Comparison of qualitative variables between patients with lower and higher PFA.

| Clinicopathological variables | Group 1 (PFA <20.2 cm², n = 151) | Group 2 (PFA ≥ 20.2 cm², n = 152) | P  |
|-------------------------------|----------------------------------|----------------------------------|----|
| **Sex**                       | Male 91 (60.3%)                  | 113 (74.3%)                      | 0.009 |
|                               | Female 60 (39.7%)                | 39 (25.7%)                       |     |
| **Surgical procedure**        | Dixon 134 (88.7%)                | 139 (91.4%)                      |     |
|                               | Miles 15 (9.9%)                  | 10 (6.6%)                        | 0.593 |
|                               | Hartmann 2 (1.3%)                | 3 (2%)                           |     |
| **Combined resection**        | No 143 (94.7%)                   | 146 (96.1%)                      | 0.576 |
|                               | Yes 8 (5.3%)                     | 6 (3.9%)                         |     |
| **Stoma**                     | No 51 (33.8%)                    | 54 (35.5%)                       | 0.749 |
|                               | Yes 100 (66.2%)                  | 98 (64.5%)                       |     |
| **Radical resection**         | No 4 (2.6%)                      | 4 (2.6%)                         | 1.000 |
|                               | Yes 147 (97.4%)                  | 148 (97.4%)                      |     |
| **Laparoscopic surgery**      | Open 129 (85.4%)                 | 123 (80.9%)                      | 0.294 |
|                               | Laparoscopic 22 (14.6%)          | 29 (19.1%)                       |     |
| **History of other cancer**   | No 147 (97.4%)                   | 150 (98.7%)                      | 0.448 |
|                               | Yes 4 (2.6%)                     | 2 (1.3%)                         |     |
| **Family history of cancer**  | No 137 (90.7%)                   | 136 (89.5%)                      | 0.715 |
|                               | Yes 14 (9.3%)                    | 16 (10.5%)                       |     |
| **Diabetes**                  | No 133 (88.1%)                   | 138 (90.8%)                      | 0.443 |
|                               | Yes 18 (11.9%)                   | 14 (9.2%)                        |     |
| **Hypertension**              | No 99 (65.6%)                    | 100 (65.8%)                      | 0.967 |
|                               | Yes 52 (34.4%)                   | 52 (34.2%)                       |     |
| **History of appendectomy**   | No 131 (86.8%)                   | 139 (91.4%)                      | 0.190 |
|                               | Yes 20 (13.2%)                   | 13 (8.6%)                        |     |
| **Concomitant polyp**         | No 137 (90.7%)                   | 133 (87.5%)                      | 0.367 |
|                               | Yes 14 (9.3%)                    | 19 (12.5%)                       |     |
| **Gross appearance**          | Ulcerative 103 (68.2%)           | 113 (74.3%)                      | 0.238 |
|                               | Protruding 48 (31.8%)            | 39 (25.7%)                       |     |
| **Differentiation**           | Poor 28 (18.5%)                  | 26 (17.1%)                       | 0.744 |
|                               | 1 13 (8.6%)                      | 4 (2.6%)                         |     |
|                               | 2 38 (25.2%)                     | 33 (21.7%)                       |     |
| **Invasion depth (T stage)**  | 3 95 (62.9%)                     | 106 (69.7%)                      | 0.077 |
|                               | 4 5 (3.3%)                       | 9 (5.9%)                         |     |
|                               | 0 94 (62.3%)                     | 72 (47.4%)                       |     |
| **Lymph node metastasis (N stage)** | 1 35 (23.2%) | 53 (34.9%) | 0.029 |
|                               | 2 22 (14.6%)                     | 27 (17.8%)                       |     |
| **Distant metastasis (M stage)** | No 137 (90.7%) | 140 (92.1%) | 0.669 |
|                               | Yes 14 (9.3%)                    | 12 (7.9%)                        |     |
| **TNM stage**                 | 3 47 (31.1%)                     | 75 (49.3%)                       | 0.013 |
|                               | 4 14 (9.3%)                      | 12 (7.9%)                        |     |
| **BRAF**                      | Wild 146 (96.7%)                 | 151 (99.3%)                      | 0.121 |
|                               | Mutant 5 (3.3%)                  | 1 (0.7%)                         |     |
| **KRAS**                      | Wild 82 (54.3%)                  | 88 (57.9%)                       | 0.529 |
|                               | Mutant 69 (45.7%)                | 64 (42.1%)                       |     |
| **Tumor deposit**             | No 126 (83.4%)                   | 102 (67.1%)                      | 0.001 |
|                               | Yes 25 (16.6%)                   | 50 (32.9%)                       |     |
weight, BMI, and TNM stage; and more lymph node metastasis and tumor deposits than patients with PFA < 20.2 cm².

PFA positively correlated with body weight and BMI. PFA increased with T stage, N stage, TNM stage, and the presence of tumor deposits and vascular invasion. Patients with EORC had a greater PFA than those with LORC. Univariate and multivariate analyses showed that PFA was an independent predictor of DFS and OS in patients with stage I–III rectal cancer. Our results indicate that perirectal fat might be involved in the carcinogenesis and development of EORC.

A large prospective study with 85,256 healthy women and 114 cases of EOCRC showed that obese women had higher incidence of EOCRC [14]. People with higher BMI at 18 years of age had a higher incidence of EOCRC and weight gain, as the patient aged 18 years had a similar effect [14]. Another large study with 583,511 participants and 3,173 cases of CRC proved that BMI ≥ 30.0 kg/m² contributed to higher incidence of EOCRC [26]. Obesity was proven to play a key role in CRC pathogenesis [27]. Multiple meta-analyses had demonstrated a consistently positive association between obesity and the incidence of CRC [10, 28–30]. Obesity can be classified into overall obesity (body weight and BMI) and abdominal obesity (waist circumference, VAT, and PFA). Abdominal obesity has been reported to be a more sensitive predictor of metabolic diseases and cancers than overall obesity [18]. Both overall obesity and abdominal obesity positively correlated with CRC incidence [27, 30], and the abdominal obesity was more sensitive than overall obesity [29]. A Korean population-based cohort study, which included 9,959,605 participants and 101,197 cases of CRC, demonstrated that a higher incidence of CRC and rectal cancer was associated with abdominal obesity, and these associations were independent of BMI [31]. In recent years, adipose tissue has proven to be the largest human endocrine organ [32]. Different from subcutaneous adipose tissue, VAT could secrete multiple cytokines and adipokines, which could promote CRC carcinogenesis and development [33–35]. Patients with higher VAT had shorter OS and DFS than those with lower VAT [36, 37]. Furthermore, VAT is a more reliable and accurate indicator than BMI in predicting the oncological outcomes of rectal cancer [38, 39].

PFA, as the closest part of the VAT surrounding the rectum, was speculated to play an active role in the carcinogenesis and progression of rectal cancer. Tripathi et al. reported that the mean PFA in a Chinese Han population, measured using pelvic MR images, was 24.0 ± 6.9 cm² [23], which was higher than the mean PFA (20.4 ± 6.9 cm²) in our study.

Table 2: Continued.

| Clinicopathological variables | Group 1 (PFA < 20.2 cm², n = 151) | Group 2 (PFA ≥ 20.2 cm², n = 152) | P  |
|-----------------------------|----------------------------------|----------------------------------|----|
| Vascular invasion           | No                               | 130 (86.1%)                      | 122 (80.3%)                      | 0.175 |
|                             | Yes                              | 21 (13.9%)                       | 30 (19.7%)                       |        |
| Perineural invasion         | No                               | 124 (82.1%)                      | 123 (80.9%)                      | 0.788 |
|                             | Yes                              | 27 (17.9%)                       | 29 (19.1%)                       |        |
| Circumferential resection margin | Negative                        | 147 (97.4%)                      | 148 (97.4%)                      | 1.000 |
|                             | Positive                         | 4 (2.6%)                         | 4 (2.6%)                         |        |
| Distal resection margin     | Negative                         | 150 (99.3%)                      | 150 (98.7%)                      | 1.000 |
|                             | Positive                         | 1 (0.7%)                         | 2 (1.3%)                         |        |
| Postoperative chemotherapy  | No                               | 43 (28.5%)                       | 44 (28.9%)                       | 0.928 |
|                             | Yes                              | 108 (71.5%)                      | 108 (71.1%)                      |        |
| Postoperative radiation     | No                               | 117 (77.5%)                      | 123 (80.9%)                      | 0.461 |
|                             | Yes                              | 34 (22.5%)                       | 29 (19.1%)                       |        |

Figure 2: Relationship between body weight, BMI, and PFA.
Figure 3: Relationship between perirectal fat area, TNM stage, tumor deposit, vascular invasion, perineural invasion, and age at diagnosis of rectal cancer. *Compared with the first group, \( P < 0.05 \). #Compared with the second group, \( P < 0.05 \).
Figure 4: The impact of PFA on DFS and OS among all patients with rectal cancer and those with stage I–III rectal cancer.

Table 3: Multivariate analysis for potential predictors of DFS in patients with stage I–III rectal cancer.

| Parameters                                      | OR (95% CI)       | P     |
|------------------------------------------------|-------------------|-------|
| Perirectal fat area (≥20.2 cm² vs. <20.2 cm²)  | 1.683 (1.126–3.015)| 0.035 |
| Diabetes (yes vs. no)                          | 1.876 (0.91–3.865)| 0.088 |
| Tumor deposit (yes vs. no)                     | 0.515 (0.25–1.06) | 0.072 |
| Vascular invasion (yes vs. no)                 | 2.695 (1.529–4.752)| 0.001 |
| Invasion depth (T3-4 vs. T1-2)                 | 2.095 (0.96–4.572) | 0.063 |
| TNM stage (3-4 vs. 1-2)                        | 3.222 (1.725–6.018)| <0.001|
This may have been caused by the difference in the series of MR images selected for measurement; they selected T2-weighted images, and we selected the fat series images. The fat series images are more specific and accurate for measuring PFA, and some areas of nonfat tissue were excluded, leading to lower PFA in our study. It was reported that viscerally obese patients with rectal cancer were more likely to be male [37], which was consistent with our results. Two other studies measured PFA using pelvic CT/MR images and found that PFA positively correlated with BMI [23, 40], which was consistent with our results. Both BMI and VAT were prognostic factors for OS and DFS in CRC [23, 40], which was consistent with our results. Both BMI and VAT were prognostic factors for OS and DFS in CRC patients [17, 41, 42]. Yoon et al. found that patients with PFA ≥ 10 cm² had significantly longer DFS than those with PFA < 10 cm², and the underlying reason remains unknown [40]. A possible hypothesis raised by the authors was that a higher PFA might increase the probability of negative resection margins. A higher PFA leads to a larger capacity for tumor cells within the MR field and then reduces the incidence of a passive circumferential resection margin [40]. However, in our study, no significant relationship was identified between PFA and the resection margin. Our study showed that in all patients, those with higher PFA had shorter DFS and similar OS than those with lower PFA. In patients with stage I–III rectal cancers, those with higher PFA had shorter DFS and OS than those with lower PFA. Patients with distant metastasis have lower PFA due to massive nutritional consumption by the tumor, and shorter DFS and OS; this might lead to contradictory results. In patients with stage IV cancers, lower PFA is associated with shorter survival, while in patients with stage I–III rectal cancers, higher PFA is associated with shorter survival. Some researchers found that low VAT was a poor prognostic marker because it could lead to impairment in nutritional supply and subsequent malnutrition [43, 44]. In addition, higher PFA might affect the surgical difficulty of TME and intersphincteric resection, leading to poor oncological outcomes [45]. This was consistent with the results of our survival analysis.

Our study and the published literature provide strong and consistent evidence that obesity is involved in CRC carcinogenesis and progression. With the development in economy and alteration in lifestyle, more people are increasingly overweight or obese [46], with 16% of children being overweight [47]. Obesity is usually measured by BMI, but the new measurement, PFA, is a more accurate predictor of CRC than BMI. Our study demonstrates that higher PFA is associated with carcinogenesis and development of EORC, and PFA may also play a crucial role in treatment sensitivity and oncological results of EORC. Measuring PFA could help us identify young individuals who might benefit from early screening and specialized surveillance for EORC. Furthermore, it could help predict the survival of patients with rectal cancer [27]. Although our evidence proves that PFA is associated with the incidence, carcinogenesis, and development of EORC, the underlying molecular mechanisms have not been completely clarified [27]. The following factors have been reported to play a vital role in the carcinogenesis and progression of EORC [27, 46, 48]: obesity-induced insulin resistance, chronic inflammation, microbiota, altered levels of adipokines, cytokines, various growth factors, adiponec- tin, and leptin. Clarifying the molecular mechanisms of PFA on EORC risk is an important strategy for preventing the increasing trend of EORC. Multiple studies have proven that microbiota dysbiosis plays a vital role in obesity, tumorigenesis, growth, immunity dysregulation, diagnosis, and chemotherapy sensitivity in CRC and EORC [49, 50]. The administration of probiotics may help microbiota to recover and reduce the incidence of obesity and CRC [49]. Diet could influence the intestinal microbiota and regulate the carcinogenesis of CRC [51]. It has been recently reported that supplementation of allium vegetables and allium-containing food could reduce the formation of preneoplastic colorectal lesions (aberrant crypt foci and adenomatous polyp) by modifying the gut microbiota and reducing the incidence and mortality of CRC [52]. Taken together, probiotics and allium vegetables may be used to modify the intestinal microbiota, decrease the risk of obesity, and thus reduce PFA and the risk of EORC. Further research is required to explore the underlying biological mechanisms regulating the relationship between PFA and EORC with the goal of unraveling a strategy to prevent EORC [27].

Our study has several limitations. First, selection bias was inevitable, as it was a retrospective study and only 21.4% (303/1418) of all patients with rectal cancer were included. This should be considered when interpreting the results. Second, our department is a tertiary referral center specialized in CRC treatment; hence, this might have resulted in more standard surgical procedures, lower incidence of positive resection margins, and better oncological results. Third, the relationship between obesity and EORC might vary in different sites of the large intestine [28, 29]. However, we only included patients with rectal cancer in this study. Another study involving the pericolon fat area is required to determine if the same effect exists in colonic cancer. Fourth, VAT was usually measured at the level of the third lumbar spine vertebra, which was not routinely covered by the pelvic MRI scan; therefore,
we could not measure VAT using pelvic MR images and compare the role of PFA with VAT.

In conclusion, we described a more accurate method for measuring PFA using fat series images from pelvic MRI scans. Our study indicates that PFA is associated with early age at diagnosis, adverse clinicopathological parameters, and poor oncological outcomes in stage I–III rectal cancer. Therefore, perirectal fat may be involved in the carcinogenesis and development of EORC. Future large prospective studies are required to verify the conclusions drawn from this study.

Data Availability

The data used to support this study are included within this article.

Ethical Approval

This study was approved by the ethics committee of the First Affiliated Hospital, Naval Medical University.

Conflicts of Interest

We declare no competing interests.

Authors’ Contributions

FS, ZW, and XHG were responsible for the conceptualization; AFP, NXZ, JW, and XHG were responsible for the original draft; AFP, NXZ, and JW were responsible for the data collection and statistical analysis; XHG was responsible for the funding acquisition; AFP, NXZ, FS, JLTK, and KZ were responsible for the investigation; FS, ZW, and XHG were responsible for the resources and supervision; AFP, NXZ, FS, JLTK, KZ, FS, ZW, and XHG were responsible for the critical revision. An Fu Pan, Nan Xin Zheng, and Jin Wang contributed equally to this work.

Acknowledgments

This work was partly funded by the Shanghai Pujiang Program (#2019PJD052), 234 Subject Climbing Plan of Shanghai Hospital (#2020YXK022), National Natural Science Foundation of China (#82072750, #81572332), and Natural Science Fund of Shanghai (20ZR1457200).

Supplementary Materials

Supplementary 1. Figure S1: flow chart of patient selection.

Supplementary 2. Table S1: univariate analysis for possible risk factors of DFS in patients with stage I–III CRC.

Supplementary 3. Table S2: univariate analysis for possible risk factors of OS in patients with stage I–III CRC.

References

[1] L. Zhang, F. Cao, G. Zhang et al., “Trends in and predictions of colorectal cancer incidence and mortality in China from 1990 to 2025,” *Frontiers in Oncology*, vol. 9, p. 98, 2019.

[2] E. M. Stoffel and C. C. Murphy, “Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults,” *Gastroenterology*, vol. 158, no. 2, pp. 341–353, 2020.

[3] G. Mauri, A. Sartore-Bianchi, A. G. Russo, S. Marsoni, A. Bardelli, and S. Siena, “Early-onset colorectal cancer in young individuals,” *Molecular Oncology*, vol. 13, no. 2, pp. 109–131, 2019.

[4] R. L. Siegel, L. A. Torre, I. Soerjomataram et al., “Global patterns and trends in colorectal cancer incidence in young adults,” *Gut*, vol. 68, no. 12, pp. 2179–2185, 2019.

[5] F. E. Vuik, S. A. Nieuwenburg, M. Bardou et al., “Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years,” *Gut*, vol. 68, no. 10, pp. 1820–1826, 2019.

[6] L. J. Hofseth, J. R. Hebert, A. Chanda et al., “Early-onset colorectal cancer: initial clues and current views,” *Nature Reviews: Gastroenterology & Hepatology*, vol. 17, no. 6, pp. 352–364, 2020.

[7] S. G. Patel and D. J. Ahnen, “Colorectal cancer in the young,” *Current Gastroenterology Reports*, vol. 20, no. 4, p. 15, 2018.

[8] C. E. Bailey, C. Y. Hu, Y. N. You et al., “Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010,” *JAMA Surgery*, vol. 150, no. 1, pp. 17–22, 2015.

[9] J. Virostko, A. Capasso, T. E. Yankelov, and B. Goodgame, “Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004–2015,” *Cancer*, vol. 125, no. 21, pp. 3828–3835, 2019.

[10] A. A. Moghaddam, M. Woodward, and R. Huxley, “Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events,” *Cancer Epidemiology, Biomarkers and Prevention*, vol. 16, no. 12, pp. 2533–2547, 2007.

[11] N. R. Smith, B. W. Jensen, E. Zimmermann, M. Gamborg, T. I. A. Sørensen, and J. L. Baker, “Associations between birth weight and colon and rectal cancer risk in adulthood,” *Cancer Epidemiology*, vol. 42, pp. 181–185, 2016.

[12] X. Zhang, K. Wu, E. L. Giovannucci et al., “Early life body fatness and risk of colorectal cancer in U.S. women and men: results from two large cohort studies,” *Cancer Epidemiology, Biomarkers and Prevention*, vol. 24, no. 4, pp. 690–697, 2015.

[13] J. Celnik, C. Ohlsson, M. Bygdell, M. Netherland, and J. M. Kindblom, “Childhood body mass index is associated with risk of adult colon cancer in men: an association modulated by pubertal change in body mass index,” *Cancer Epidemiology, Biomarkers and Prevention*, vol. 28, no. 5, pp. 974–979, 2019.

[14] P. H. Liu, K. Wu, K. Ng et al., “Association of obesity with risk of early-onset colorectal cancer among women,” *JAMA Oncology*, vol. 5, no. 1, pp. 37–44, 2019.

[15] M. Song, F. B. Hu, D. Spiegelman et al., “Adulthood weight change and risk of colorectal cancer in the nurses’ health study and health professionals follow-up study,” *Cancer Prevention Research*, vol. 8, no. 7, pp. 620–627, 2015.

[16] M. Song, F. B. Hu, D. Spiegelman et al., “Long-term status and change of body fat distribution, and risk of colorectal cancer: a prospective cohort study,” *International Journal of Epidemiology*, vol. 45, no. 3, pp. 871–883, 2016.

[17] B. Doleman, K. T. Mills, S. Lim, M. D. Zelhart, and G. Gagliardi, “Body mass index and colorectal cancer prognosis: a systematic review and meta-analysis,” *Techniques in Coloproctology*, vol. 20, no. 8, pp. 517–535, 2016.
[18] U. Smith, “Abdominal obesity: a marker of ectopic fat accumulation,” *Journal of Clinical Investigation*, vol. 125, no. 5, pp. 1790–1792, 2015.

[19] H. G. Moon, Y. T. Ju, C. Y. Jeong et al., “Visceral obesity may affect oncologic outcome in patients with colorectal cancer,” *Annals of Surgical Oncology*, vol. 15, no. 7, pp. 1918–1922, 2008.

[20] Y. Dong, J. Zhou, Y. Zhu et al., “Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies,” *Bioscience Reports*, vol. 37, no. 6, 2017.

[21] X. H. Gao, N. Lan, H. Chouhan, L. Stocchi, E. Remer, and B. Shen, “Pelvic MRI and CT images are interchangeable for measuring peripouch fat,” *Scientific Reports*, vol. 7, no. 1, article 12443, 2017.

[22] N. Keum, D. H. Lee, R. Kim, D. C. Greenwood, and E. L. Giovannucci, “Visceral adiposity and colorectal adenomas: dose-response meta-analysis of observational studies,” *Annals of Oncology*, vol. 26, no. 6, pp. 1101–1109, 2015.

[23] P. Tripathi, Y. Hai, Z. Li, Y. Shen, X. Hu, and D. Hu, “Morphometric assessment of the mesorectal fat in Chinese Han population: a clinical MRI study,” *Science Progress*, vol. 104, no. 2, 2021.

[24] M. A. Wadud, A. Sharaf, I. Roy et al., “Validation of a semi-automated technique to accurately measure abdominal fat distribution using CT and MRI for clinical risk stratification,” *British Journal of Radiology*, vol. 90, no. 1071, article 20160662, 2017.

[25] X. H. Gao, H. Chouhan, G. L. Liu et al., “Peripouch fat area measured on MRI image and its association with adverse pouch outcomes,” *Inflammatory Bowel Diseases*, vol. 24, no. 4, pp. 806–817, 2018.

[26] N. N. Sanford, E. L. Giovannucci, C. Ahn, E. C. Dee, and B. A. Mahal, “Obesity and younger versus older onset colorectal cancer in the United States, 1998–2017,” *Journal of Gastrointestinal Oncology*, vol. 11, no. 1, pp. 121–126, 2020.

[27] C. Jochem and M. Leitzmann, “Obesity and colorectal cancer,” *Recent Results in Cancer Research*, vol. 208, pp. 17–41, 2016.

[28] S. C. Larsson and A. Wolk, “Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies,” *American Journal of Clinical Nutrition*, vol. 86, no. 3, pp. 556–565, 2007.

[29] Z. Dai, Y. C. Xu, and L. Niu, “Obesity and colorectal cancer risk: a meta-analysis of cohort studies,” *World Journal of Gastroenterology*, vol. 13, no. 31, pp. 4199–4206, 2007.

[30] Y. Ma, Y. Yang, F. Wang et al., “Obesity and risk of colorectal cancer: a systematic review of prospective studies,” *PLoS One*, vol. 8, no. 1, article e53916, 2013.

[31] G. E. Nam, S. J. Baek, H. B. Choi et al., “Association between abdominal obesity and incident colorectal cancer: a nationwide cohort study in Korea,” *Cancers*, vol. 12, no. 6, p. 1368, 2020.

[32] M. Coelho, T. Oliveira, and R. Fernandes, “Biochemistry of adipose tissue: an endocrine organ,” *Archives of Medical Science*, vol. 9, no. 2, pp. 191–200, 2013.

[33] D. B. Liesenfeld, D. Grapov, J. F. Fahrmann et al., “Metabolomics and transcriptomics identify pathway differences between visceral and subcutaneous adipose tissue in colorectal cancer patients: the ColoCare study,” *American Journal of Clinical Nutrition*, vol. 102, no. 2, pp. 433–443, 2015.

[34] N. Nagata, K. Sakamoto, T. Arai et al., “Visceral abdominal fat measured by computed tomography is associated with an increased risk of colorectal adenoma,” *International Journal of Cancer*, vol. 135, no. 10, pp. 2273–2281, 2014.

[35] E. K. Choe, D. Kim, H. J. Kim, and K. J. Park, “Association of visceral obesity and early colorectal neoplasia,” *World Journal of Gastroenterology*, vol. 19, no. 45, pp. 8349–8356, 2013.

[36] C. S. Lee, D. J. Murphy, C. McMahon et al., “Visceral adiposity is a risk factor for poor prognosis in colorectal cancer patients receiving adjuvant chemotherapy,” *Journal of Gastrointestinal Cancer*, vol. 46, no. 3, pp. 243–250, 2015.

[37] W. Clark, E. M. Siegel, Y. A. Chen et al., “Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation,” *Journal of the American College of Surgeons*, vol. 216, no. 6, pp. 1070–1081, 2013.

[38] A. P. Thrift, J. Gong, U. Peters et al., “Mendelian randomization study of body mass index and colorectal cancer risk,” *Cancer Epidemiology, Biomarkers and Prevention*, vol. 24, no. 7, pp. 1024–1031, 2015.

[39] J. Kang, S. E. Baek, T. Kim et al., “Impact of fat obesity on laparoscopic total mesorectal excision: more reliable indicator than body mass index,” *International Journal of Colorectal Disease*, vol. 27, no. 4, pp. 497–505, 2012.

[40] J. Yoon, Y. E. Chung, J. S. Lim, and M. J. Kim, “Quantitative assessment of mesorectal fat: new prognostic biomarker in patients with mid-to-lower rectal cancer,” *European Radiology*, vol. 29, no. 3, pp. 1240–1247, 2019.

[41] A. S. Rickles, J. C. Iannuzzi, O. Mironov et al., “Visceral obesity and colorectal cancer: are we missing the boat with BMI?” *Journal of Gastrointestinal Surgery*, vol. 17, no. 1, pp. 133–143, 2013.

[42] N. Ballian, M. G. Lubner, A. Munoz et al., “Visceral obesity is associated with outcomes of total mesorectal excision for rectal adenocarcinoma,” *Journal of Surgical Oncology*, vol. 105, no. 4, pp. 365–370, 2012.

[43] L. Santarpia, F. Contaldo, and F. Pasanisi, “Nutritional screening and early treatment of malnutrition in cancer patients,” *Journal of Cachexia, Sarcopenia and Muscle*, vol. 2, no. 1, pp. 27–35, 2011.

[44] F. Bozzetti, “Nutritional support of the oncology patient,” *Critical Reviews in Oncology/Hematology*, vol. 87, no. 2, pp. 172–200, 2013.

[45] S. Huang, M. Chen, Y. Deng et al., “Mesorectal fat area and mesorectal area affect the surgical difficulty of robotic-assisted mesorectal excision and intersphincteric resection respectively in different ways,” *Colorectal Disease*, vol. 22, no. 9, pp. 1130–1138, 2020.

[46] J. Martinez-Useros and J. Garcia-Fonciillas, “Obesity and colorectal cancer: molecular features of adipose tissue,” *Journal of Translational Medicine*, vol. 14, no. 1, p. 21, 2016.

[47] S. Pendyala and P. Holt, “Obesity and colorectal cancer risk,” *Gastroenterology*, vol. 134, no. 3, p. 896, 2008.

[48] E. S. Blomain and S. A. Waldman, “Does obesity promote the development of colorectal cancer?,” *Expert Review of Anticancer Therapy*, vol. 16, no. 5, pp. 465–467, 2016.

[49] F. Odun-Ayo and L. Reddy, “Gastrointestinal microbiota dysbiosis associated with SARS-CoV-2 infection in colorectal cancer: the implication of probiotics,” *Gastroenterology Insights*, vol. 13, no. 1, pp. 35–59, 2022.

[50] M. Abdullah, N. Sukartini, S. A. Nusraywan et al., “Gut microbiota profiles in early- and late-onset colorectal cancer: a
potential diagnostic biomarker in the future,” *Digestion*, vol. 102, no. 6, pp. 823–832, 2021.

[51] J. Yang and J. Yu, “The association of diet, gut microbiota and colorectal cancer: what we eat may imply what we get,” *Protein & Cell*, vol. 9, no. 5, pp. 474–487, 2018.

[52] A. Forma, Z. Chilimoniuk, J. Januszewski, and R. Sitarz, “The potential application of allium extracts in the treatment of gastrointestinal cancers,” *Gastroenterology Insights*, vol. 12, no. 2, pp. 136–146, 2021.